anti-CDH17/anti-CEACAM5 bispecific antibody drug conjugate (Haisco)

N/A

Report date: 2026/05/27 17:57:54

Base Information

Drug Nameanti-CDH17/anti-CEACAM5 bispecific antibody drug conjugate (Haisco)
Drug Alias Nameanti-CDH17/anti-CEACAM5 bispecific ADC(Haisco)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Cadherin-17Anti-CEACAM5
TargetsCadherin-17Carcinoembryonic antigen related cell adhesion molecule 5
Therapy Area/IndicationsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHaisco Pharmaceutical Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHaisco Pharmaceutical Group Co Ltd
Inactive CompaniesN/A
Active IndicationsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A